Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

September 03, 2013; 81 (10) Global Perspectives

The global epidemiology of herpes zoster

Barbara P. Yawn, Don Gilden
First published September 2, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182a3516e
Barbara P. Yawn
From the Department of Research (B.P.Y.), Olmsted Medical Center, Rochester, MN; and Departments of Neurology and Microbiology (D.G.), University of Colorado School of Medicine, Aurora.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Don Gilden
From the Department of Research (B.P.Y.), Olmsted Medical Center, Rochester, MN; and Departments of Neurology and Microbiology (D.G.), University of Colorado School of Medicine, Aurora.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
The global epidemiology of herpes zoster
Barbara P. Yawn, Don Gilden
Neurology Sep 2013, 81 (10) 928-930; DOI: 10.1212/WNL.0b013e3182a3516e

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
5285

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Varicella-zoster virus (VZV) is a ubiquitous, highly neurotropic, exclusively human α-herpesvirus. Primary infection usually results in varicella (chickenpox), after which VZV becomes latent in neurons of cranial nerve ganglia, dorsal root ganglia, and autonomic ganglia along the entire neuraxis. As humans undergo a natural decline in cell-mediated immunity (CMI) to VZV with age, VZV frequently reactivates to produce zoster, characterized by maculopapular or vesicular rash and dermatomal-distribution pain. Pain and rash usually occur within days of each other. Pain is severe and often burning. Colorful descriptions of zoster exist worldwide. In Arabic, Hezam innar Embedded Image means belt of fire; in Hindi, Baoisayaa daga Embedded Image means big rash; in Norwegian, Helvetesild means Hell's fire (also described as a bell of roses from Hell); and in Spanish, Culebrilla means small snake.1 The most common complication of zoster is postherpetic neuralgia (PHN), operationally defined as pain lasting for more than 90 days after rash. Zoster may be followed by multiple neurologic disorders (meningoencephalitis, myelitis, and vasculopathy, including VZV temporal arteritis) as well as ocular disease (acute or progressive outer retinal necrosis).

Primary VZV infection produces VZV antibody and VZV-specific T-CMI. Serum of individuals 60–94 years old contains variable antibodies to VZV glycoproteins I–IV and to 3 nonglycosylated proteins; VZV antibodies in some elderly individuals with no history of varicella or zoster indicate subclinical infection. VZV antibodies do not protect against zoster or PHN. Recovery from varicella is associated with VZV-specific T-CMI, detected 1–2 weeks after disappearance of rash, consisting of CD4, CD8 effector, and memory T cells. T-cell immunity to VZV is more important than antibodies. Agammaglobulinemic patients do not produce VZV-specific antibodies but are protected against second episodes of varicella because they mount VZV-specific T-CMI responses. Individuals with T-CMI deficiency disorders or who are immunosuppressed have more zoster and more severe disease than normal hosts. In human stem cell recipients who received inactivated VZV vaccine, protection correlated with VZV-specific T-CMI but not with anti-VZV antibody.

Nearly all children develop varicella and become latently infected. Attenuated VZV in varicella vaccine also becomes latent after childhood vaccination. Thus, zoster remains a global health issue, awaiting the development of a vaccine that produces permanent immunity and prevents virus reactivation. VZV-specific T-CMI maintains VZV in a latent state in ganglia. Immunity is boosted by subclinical reactivation of virus or environmental exposure. Zoster increases with age as VZV-specific T-CMI declines, evident even during the first 3 years after varicella, when VZV-specific memory CD4 T cells decrease. After mid-life, antigenic stimulation provided by re-exposure and asymptomatic reactivation are not sufficient to maintain VZV-specific T-cell immunity. Comparison of CMI response to VZV antigen in vitro in young adults and individuals over age 60 years revealed 5-fold fewer CD4 cells producing interferon-γ or interleukin-4 and -5, as well as fewer CD4 early effectors and CD8 effector memory cells in older age groups. Recognition of the essential role of CMI to VZV for protection against and recovery from varicella and zoster led to studies designed to boost CMI to VZV by immunization of elderly adults.

Any epidemiologic overview of zoster must highlight important caveats. Data from health care systems are limited to medically attended cases and may miss those that are milder or less able to access the medical system. Hospital-based data are particularly prone to artifacts. The prevalence of zoster risk factors within selected study populations can cause substantial differences in observed zoster incidence. Studies using varied methods and conducted in different populations in the United States, Canada, South America, Europe, Asia, and Australia revealed a median zoster incidence of 4–4.5 per 1,000 person-years.e1–e9 The age-adjusted incidence of zoster is increasing.2,3 In Olmsted County, Minnesota, zoster rates increased 28% over 5 years, from 3.2 (95% confidence interval [CI] 2.9–3.5) per 1,000 person-years in 1996–1997 to 4.1 (95% CI 3.8–4.4) in 2000–2001, an increase not explained by changes in age distribution or the prevalence of immunocompromised persons.4 Similar increases over variable time periods have been seen in most, but not all, analyses conducted in the United States, Canada, Europe, Asia, and Australia, but the reasons for these increases are unknown.

All studies show a striking increase of zoster with age, particularly after age 50 years (figure). The mean age at onset of zoster among adults (age 22 years and older) is 59.4 years, with 68% of cases occurring in those 50 years and older. Age-adjusted rates are higher in women than in men (3.9 vs 3.2 per 1,000 person-years, respectively; p < 0.0001). Based upon these age-specific rates, ∼1 million new episodes of zoster have been estimated to occur in the United States yearly (table), with a lifetime risk of ∼30%.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Age-specific zoster incidence rates around the world

Compiled by E. Brenitz, MD, PhD, Merck and Co., for ICID, Bangkok, Thailand, June 2012. See also references e1–e9 on the Neurology® Web site at www.neurology.org.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

Incidence of zoster and postherpetic neuralgia: Extrapolation of 2000–2001 rates in Olmsted County, Minnesota, to the US population in 2010

In the United States, ∼8% of zoster episodes occur in immunocompromised patients2 (e.g., organ transplant recipients, patients treated with cytotoxic drugs or irradiation, and those with HIV/AIDS). In patients with HIV/AIDS, the risk of zoster varies with stage of HIV infection and treatment, but rates are typically increased many-fold, and episodes can be recurrent and protracted. In regions most affected by the HIV/AIDS pandemic, zoster in young adults is often a marker of HIV infection. Given that globally ∼34 million people are infected with HIV, zoster rates are clearly affected, although data relating to the impact of the HIV/AIDS pandemic on zoster incidence are not available.

PHN also increases with age. Among persons older than 50 years and 80 years, the incidence of PHN in zoster patients is 18% and 33%, respectively. Overall, 80% of all PHN occurs among persons 50 years and older (table).

About 3% of patients with zoster are hospitalized.2,5 Few studies provide valid data relating to zoster mortality, with only ∼0.25 per million population in the United States and Europe, mostly among the elderly. Reported rates of recurrent zoster vary from 3% to 5% lifetime to 6.2% over 8 years,2 and are clearly associated with decreased immune competency. For individuals with HIV, the recurrence rate can be as high as 13% to 26%. Zoster mortality is presumably elevated in countries severely affected by the HIV/AIDS pandemic.

Varicella vaccine is used in a growing number of countries. Attenuated vaccine VZV becomes latent and can reactivate to cause zoster, although risk of vaccine-associated zoster is a fraction of the risk of zoster after natural infection. Over time, countries having varicella vaccination programs may experience less zoster. However, the low incidence of varicella in countries with vaccination programs has reduced opportunities for exposure to varicella and for boosting of VZV-specific immunity. Thus, in those countries, vaccination might lead to increased rates of zoster. Age-specific increases in zoster incidence have already been noted in a number of countries (see above), but similar increases have occurred in the presence and the absence of varicella vaccination programs. While immunization programs continue to monitor the impact of varicella vaccination on age-adjusted zoster incidence, the increasing trends remain unexplained.

In a number of countries, a vaccine (Zostavax) to prevent zoster is recommended for older adults. Vaccine efficacy is 51% for prevention of zoster and 65% for prevention of PHN lasting 90 days or more. However, vaccine has not yet affected the epidemiology of zoster, because uptake has been low, reaching 14.4% in the United States 4 years after licensure (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a2.htm). Barriers to uptake in the United States have included high cost, requirement for freezer storage, complex insurance reimbursement, and vaccine supply failures.

STUDY FUNDING

Supported in part by NIH grants AG006127 and AG032958 to D.G. and a grant from CDC to B.P.Y.

DISCLOSURE

D. Gilden receives research support from NIH research grants AG006127, AG03258, and NS007321. Dr. Gilden serves as Senior Associate Editor for the Journal of Neurovirology and on the editorial boards of In Vivo, Journal of Virology, Scientific American Medicine, Virus Genes, and Neurology®. Dr. Gilden has consulted for TEVA and Epiphany Laboratories and has received payment for educational lectures from Merck Laboratories. B. Yawn reports no disclosures. Go to Neurology.org for full disclosures.

Footnotes

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Supplemental data at www.neurology.org

  • © 2013 American Academy of Neurology

REFERENCES

  1. 1.↵
    1. Paek E,
    2. Johnson R
    . Public awareness and knowledge of herpes zoster: results of a global survey. Gerontology 2010;56:20–31.
    OpenUrlPubMed
  2. 2.↵
    1. Yawn BP,
    2. Saddier P,
    3. Wollan PC,
    4. St Sauver JL,
    5. Kurland MJ,
    6. Sy LS
    . A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341–1349.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Lu PJ,
    2. Euler GL,
    3. Harpaz R
    . Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med 2011;40:e1–e6.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Naveen KN,
    2. Tophakane RS,
    3. Hanumanthayya K,
    4. Pv B,
    5. Pai VV
    . A study of HIV seropositivity with various clinical manifestation of herpes zoster among patients from Karnataka, India. Dermatol Online J 2011;17:3.
    OpenUrlPubMed
  5. 5.↵
    1. Lydick E,
    2. Epstein RS,
    3. Himmelberger D,
    4. White CJ
    . Herpes zoster and quality of life: a self- limited disease with severe impact. Neurology 1995;45(suppl 8):S52–S53.
    OpenUrlFREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • STUDY FUNDING
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Topics Discussed

  • Neuropathic pain
  • Viral infections

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Clinical and Ethical Challenges
    The challenging patient with varicella-zoster virus disease
    Maria A. Nagel, Don Gilden et al.
    Neurology: Clinical Practice, April 15, 2013
  • Articles
    Herpes zoster ophthalmicus and the risk of stroke
    A population-based follow-up study
    Herng-Ching Lin, Ching-Wen Chien, Jau-Der Ho et al.
    Neurology, March 03, 2010
  • Articles
    The varicella zoster virus vasculopathies
    Clinical, CSF, imaging, and virologic features
    M. A. Nagel, R. J. Cohrs, R. Mahalingam et al.
    Neurology, March 10, 2008
  • Articles
    Varicella zoster virus vasculopathy
    Analysis of virus-infected arteries
    M.A. Nagel, I. Traktinskiy, Y. Azarkh et al.
    Neurology, July 13, 2011
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise